Related references
Note: Only part of the references are listed.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
N. S. Ding et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis
M. J. Rosen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation
Kaija-Leena Kolho et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study
Ryota Iwasa et al.
BMC GASTROENTEROLOGY (2015)
Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
Shomron Ben-Horin et al.
BMC GASTROENTEROLOGY (2015)
A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
Maria Theresa Arias et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials
Jennifer L. Jones et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
Henit Yanai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
David J. Gibson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation
Nikos Viazis et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Immunogenicity to infliximab is associated with HLA-DRB1
Thomas Billiet et al.
GUT (2015)
Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort
Pascal Juillerat et al.
INFLAMMATORY BOWEL DISEASES (2015)
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients
Florenzo Lannone et al.
JOINT BONE SPINE (2015)
P471. Infliximab trough levels are lower in patients with acute severe, compared to moderate-severe ulcerative colitis patients
Journal of Crohns & Colitis (2015)
Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
Bella Ungar et al.
MEDICINE (2015)
Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients
Silvo Koder et al.
PHARMACOGENOMICS (2015)
565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)
Brian G. Feagan et al.
GASTROENTEROLOGY (2015)
Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors of Clinical and Laboratory Response in Crohn's Disease Patients
Yoav Mazor et al.
GASTROENTEROLOGY (2015)
Smoking and Early Infliximab Response in Crohn's Disease: a Meta-analysis
Sumant Inamdar et al.
JOURNAL OF CROHNS & COLITIS (2015)
Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis
David Kevans et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment
M. R. K. L. Lie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment
Gordon W. Moran et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Jean-Frederic Colombel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year
Luisa Guidi et al.
DIGESTIVE AND LIVER DISEASE (2014)
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease
Ana Gutierrez et al.
GUT (2014)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Clinical Utility of Fecal Biomarkers for the Diagnosis and Management of Inflammatory Bowel Disease
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2014)
Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
Uri Kopylov et al.
JOURNAL OF CROHNS & COLITIS (2014)
High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2014)
Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
Charlotte P. Peters et al.
JOURNAL OF CROHNS & COLITIS (2014)
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
Raja Atreya et al.
NATURE MEDICINE (2014)
The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease
Kaija-Leena Kolho et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2014)
Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease
Diamantis Thomas et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Surgical treatment of ulcerative colitis: Ileorectal vs ileal pouch-anal anastomosis
Daniele Scoglio et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors
A. C. Moss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis
Masa Umicevic Mirkov et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Shomron Ben-Horin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
Mahesh Bhalme et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2013)
Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease
Jason W. Harper et al.
INFLAMMATORY BOWEL DISEASES (2013)
Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy
Martine De Vos et al.
INFLAMMATORY BOWEL DISEASES (2013)
Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2013)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
N. Vande Casteele et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center
Russell D. Cohen et al.
INFLAMMATORY BOWEL DISEASES (2012)
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
Pauliina Molander et al.
INFLAMMATORY BOWEL DISEASES (2012)
Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2012)
P360 Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease: A single cohort study
M. Bortlik et al.
Journal of Crohns & Colitis (2012)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
Matthias Jurgens et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
Jean Frederic Colombel et al.
GASTROENTEROLOGY (2011)
Epidemiology and Natural History of Inflammatory Bowel Diseases
Jacques Cosnes et al.
GASTROENTEROLOGY (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Combination of Genetic and Quantitative Serological Immune Markers are Associated with Complicated Crohn's Disease Behavior
Gary R. Lichtenstein et al.
INFLAMMATORY BOWEL DISEASES (2011)
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
A.A. Fasanmade et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis
Matthias Juergens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
Harry Sokol et al.
GUT (2010)
Monitoring Functional Serum Antitumor Necrosis Factor Antibody Level in Crohn's Disease Patients Who Maintained and Those Who Lost Response to Anti-TNF
Akihiro Yamada et al.
INFLAMMATORY BOWEL DISEASES (2010)
Genome Wide Association (GWA) Predictors of Anti-TNFα Therapeutic Responsiveness in Pediatric Inflammatory Bowel Disease
Marla C. Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis
G. T. Ho et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Does smoking reduce infliximab's effectiveness against Crohn's disease?
Neeraj Narula et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
Corey A. Siegel et al.
Therapeutic Advances in Gastroenterology (2009)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Long-term outcome after infliximab for refractory ulcerative colitis
Marc Ferrante et al.
JOURNAL OF CROHNS & COLITIS (2008)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
Tibor Hlavaty et al.
INFLAMMATORY BOWEL DISEASES (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
P Rutgeerts et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study
A Orlando et al.
DIGESTIVE AND LIVER DISEASE (2005)
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys
JR Rojas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
Elena Urcelay et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease
DS Fefferman et al.
INFLAMMATORY BOWEL DISEASES (2004)
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease:: A prospective cohort study
S Vermeire et al.
GASTROENTEROLOGY (2003)
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease
IDR Arnott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
NOD2/CARD15 does not influence response to infliximab in Crohn's disease
S Vermeire et al.
GASTROENTEROLOGY (2002)
Long-term evolution of disease behavior of Crohn's disease
J Cosnes et al.
INFLAMMATORY BOWEL DISEASES (2002)
Share Paper
